Journal of Clinical Oncology
Articles in this Issue
Safety, efficacy, and outcomes of 90-yttrium radioembolization in combination with immune checkpoint inhibitors as a definitive first-line treatment approach in non-surgical hepatocellular carcinoma.
617 Background: Immune checkpoint inhibitors (ICI) have emerged as first line therapy for advanced-stage hepatocellular carcinoma (HCC). However, response...
Influence of preoperative Lynch syndrome diagnosis on surgery in patients with colorectal cancer.
94 Background: Lynch Syndrome (LS) can guide surgery for colorectal cancer (CRC), particularly for MLH1/MSH2 carriers, who may ben...
Conversion from radical esophagectomy to definitive chemoradiotherapy after neoadjuvant chemotherapy for advanced esophageal squamous cell carcinoma: Treatment options based on chemotherapy response.
408 Background: Radical esophagectomy after neoadjuvant chemotherapy (NAC) is the established strategy for resectable advanced esophageal cancer. However,...
Comparing outcomes for early and late drainage of malignant ascites.
842 Background: Malignant ascites (MA) is a common sequela of peritoneal carcinomatosis resulting in significant morbidity and poses substantial managemen...
Pattern and predictors of D3 lymph node station positivity in patients undergoing curative surgery for adenocarcinoma of colon.
137 Background: The prognosis and surgical management of colon cancer is intricately related to its lymphatic drainage. The oncological outcome of apical...
An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.
390 Background: Combining epigenetic modulator with PD-1 inhibitor may enhance treatment outcomes in cancer patients. This study aimed to evaluate the eff...
Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable <i>BRAF</i> <sup>V600E</sup> metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies.
182 Background: A BRAF V600E mutation, present in approximately 8-10% of all colorectal...
Safety and efficacy of anti-HER2 agents in the treatment of biliary tract cancers: A systematic review.
639 Background: Limited treatment options exist for patients with locally advanced or metastatic biliary tract cancers (BTCs). Recently, several clinical...
Association of malnutrition at diagnosis with survival among older adults with pancreatic cancer.
680 Background: Malnutrition is common among older adults newly diagnosed with pancreatic cancer. However, the implications of malnutrition among this vul...
Prediction of immunotherapy response in deficient mismatch repair colorectal cancers using an immune-enhanced exome and transcriptome platform.
270 Background: While immune checkpoint blockade (ICB) is used to treat metastatic deficient mismatch repair (dMMR) colorectal cancers (CRCs), such tumors...
Outcomes of durvalumab (D) with or without tremelimumab (T) in routine clinical practice according to HIMALAYA trial eligibility: Preliminary results of the international DT-real study.
552 Background: HIMALAYA showed that D+T and D are effective options for unresectable hepatocellular carcinoma (uHCC). However, data on outcomes according...
A 20-year population-wide cohort study on association of aspirin and risk of gastrointestinal and non-gastrointestinal cancer.
830 Background: Aspirin has been shown to reduce the risk of various gastrointestinal (GI) and non-GI cancers 1,2 . However, littl...
Clinical characteristics and treatment outcomes for metastatic early-onset small bowel adenocarcinoma treated with first-line chemotherapy.
796 Background: Small bowel adenocarcinoma (SBA) is an aggressive rare cancer with its incidence on the rise. Although early-onset SBA (EO-SBA: diagnosed...
Phase Ib/II study of fruquintinib plus 5-fluorouracil/leucovorin after progression on fruquintinib monotherapy in metastatic colorectal cancer.
128 Background: Fruquintinib is a standard third-line treatment in metastatic colorectal cancer (mCRC). However, no standard therapeutic regimen is availa...
Optimal preoperative treatment strategy for conversion surgery in unresectable locally advanced pancreatic cancer: A project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
718 Background: Conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC) has been widely accepted when feasible. However, opt...
Genomic alterations as predictive biomarkers for cancer-associated thrombosis (CAT) in biliary tract cancer (BTC).
634 Background: CAT is the second leading cause of cancer-related death, yet the genetic underpinnings of VTE risk in BTC remain underexplored. The evalua...
Neoadjuvant immunotherapy and nonoperative management of dMMR gastroesophageal adenocarcinoma (GEA): A retrospective case series.
451 Background: Perioperative chemotherapy with surgery is the standard of care for patients (pts) with resectable gastric or gastroesophageal junction ad...
Phase 1/2 study of the HER3-directed antibody-drug conjugate patritumab deruxtecan (MK-1022) as monotherapy in patients with gastrointestinal cancers.
TPS321 Background: A significant medical need exists for more effective and tolerable therapeutic options for patients with advanced gastrointestinal canc...
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
826 Background: After initial response to first line therapy with imatinib, GISTs commonly progress due to secondary resistance mutations in KIT. As the K...
Uncovering the role of oncogenic <i>HER2</i> variants as drivers of pancreatic cancer.
772 Background: The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) to conventional cytotoxic therapy underscores the need for advances...
Total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for locoregionally advanced low rectal cancer: A phase III randomized controlled trial (JCOG2207).
TPS312 Background: For locally advanced low rectal cancer (RC), total neoadjuvant therapy (TNT) followed by total mesorect...
MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with <i>KRAS</i> G12R alteration.
725 Background: Pancreatic ductal adenocarcinoma (PDAC) is largely driven by oncogenic alterations in the KRAS , TP53...
Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
601 Background: Although radical resection offers one of the most favorable prognosis for hepatocellular carcinoma (HCC), the rate of postoperative recurr...
Adherence to multi-target stool DNA test in the US Asian population from 2017-2024.
101 Background: In 2024, incidence and mortality cases related to colorectal cancer (CRC) in the US are estimated to reach...
Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks.
340 Background: Upper gastrointestinal (GI) tract cancers represent a significant global health burden, characterized by h...